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The frequent development of drug resistance to targeted therapies in cancer patients
has stimulated interest in strategies counteracting resistance. Combining immunother-
apies with targeted therapies is one such strategy. In this context, we asked whether
human NK cells can target melanoma cells that have acquired resistance to selective
inhibitors targeting activating mutants of the B-Raf kinase (BRAF inhibitors, BRAFi). We
generated drug-resistant cell variants in vitro from human BRAF-mutant melanoma cell
lines MEL-HO, COLO-38, SK-MEL-37, 1520 and from primary melanoma cells freshly iso-
lated from two patients. All drug-resistant cell variants remained susceptible to lysis by
IL-2-activated NK cells; and two BRAFi-resistant lines (BRAFi-R) became significantlymore
susceptible to NK-cell lysis than their parental lines. This was associated with significant
HLA class I antigen downregulation and PD-L1 upregulation on the drug-resistant lines.
Although blocking HLA class I enhanced the extent of lysis of both BRAFi-R and parental
cells to NK-cell-mediated lysis, antibody-mediated inhibition of PD1–PD-L1 interactions
had no detectable effect. HLA class I antigen expression on BRAFi-R melanoma variants
thus appears to play a major role in their susceptibility to NK-cell cytotoxicity. These
findings suggest that NK-cell-based immunotherapy may be a viable approach to treat
melanoma patients with acquired resistance to BRAF inhibitors.
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Introduction
Activation mutations in the serine-threonine kinase B-Raf are the
most prevalent genetic lesions in malignant melanoma, with the
V600E mutation in the BRAF gene being the most common [1].
BRAF inhibitors (BRAFi), such as the BRAFV600E–specific vemu-
rafenib, also known as PLX4032, and dabrafenib, which targets
BRAFV600E and also other mutant BRAF variants, significantly pro-
long overall survival of melanoma patients carrying these muta-
tions [2, 3]. Most patients treated with BRAFi, however, develop
drug-resistant tumors [4] and this is a major challenge.
New immunotherapies that target immune checkpoints, such
as PD-1 and its ligand PD-L1, also offer survival gains to patients
with metastatic melanoma, with durable response rates varying
from 20 to 50% [5]. Strategies are being tested to improve the
response rates by combining immunotherapies with therapies that
target mutant activated BRAF or its downstream pathway compo-
nents [6, 7]. For example, BRAFi enhance PD-L1 expression on
melanoma cells [8], providing an argument for combining thera-
pies that target both BRAF and the PD-1 pathway.
NK cells are innate immune cells that spontaneously lyse tumor
cells, mediate antibody-dependent cellular cytotoxicity and regu-
late adaptive immunity through production of cytokines. These
functional properties make them an attractive target to co-opt
in immunotherapies for cancer patients. NK cells are activated
by HLA class I molecule downregulation/loss on tumor cells, a
frequent occurrence in cancer cells [9, 10]. On the other hand,
pharmacological agents that target cancer cells, such as dacar-
bazine [11], and P53 activators [12–14] induce the expression of
stress-induced molecules on melanoma cells that alert NK cells
specifically through the NKG2D receptor.
The molecular mechanisms that regulate NK-cell-mediated
recognition of cancer cells include both activating (NCRs, NKG2D,
DNAM-1, NKG2C) and inhibitory (KIR, NKG2A) receptors [15–
18]. T-cell inhibitory receptors PD-1, CTLA-4 and TIM-3, which
respectively bind PD-L1/PD-L2, B7-1/B7-2 and Galectin-9, can
also be induced in NK cells and regulate their function [19–22].
The effects of BRAFi on the crosstalk between melanoma cells
and NK cells are unknown and here we set out to investigate
them.We generated BRAFi-resistant variants from four established
BRAFV600E and two freshly explanted human melanoma cell lines
in vitro and measured: their susceptibility to lysis mediated by
IL-2 activated NK cells from healthy donors; expression of NK-cell
receptor ligands and HLA class I antigen processing machinery
(APM) components in melanoma cells before and after acquisi-
tion of resistance to BRAFi vemurafenib or dabrafenib and effects
of BRAFi on NK cells.
Results
Generation of BRAFi-resistant melanoma cell lines
We cultured the BRAFV600E mutant melanoma cell lines in the
presence of BRAFi vemurafenib or dabrafenib at 5 μM for 30
Figure 1. Effects of BRAFi on in vitro cell growth/viability of drug-
sensitive and -resistant melanoma cell lines harboring BRAFV600E. The
drug-sensitive and -resistant melanoma cell lines MEL-HO and MEL-
HO-R respectively were evaluated for sensitivity to BRAFi follow-
ing 4 days culture in the presence of the indicated concentrations
of dabrafenib (left) or vemurafenib (right). Cell growth/viability were
determined by ATP assay (CellTiter-Glo). Data are expressed as the
mean luminescence ± SEM of the results pooled from three individ-
ual experiments.
Table 1. Human melanoma cell lines used in this study
Cell line BRAF status and other
known mutations
References
MEL-HO BRAFV600E, PTEN [47]
COLO-38 BRAFV600E [48]
SK-MEL-37 BRAFV600E, PTEN, TP53 [49]
1520 BRAFV600E [50]
Mel 30 BRAFV600E N.A.
Mel 35 BRAFV600E N.A.
N.A.: not applicable
days. Exposure to dabrafenib for at least 30 days lead to the emer-
gence of a dabrafenib-resistant variant of MEL-HO cells (MEL-HO-
R) that displayed increased resistance to dabrafrenib and cross-
resistance to vemurafenib, compared to the parental cell line (p
< 0.0004) (Fig. 1). Similar experiments were done using other
BRAFV600E mutant melanoma cell lines (COLO-38, SK-MEL-37 and
1520, Table 1), and primary melanoma cell lines (Mel 30 and Mel
35, Table 1). The BRAFi-resistant variants are thereafter referred
to as MEL-HO-R, COLO-38-R, SK-MEL-37-R, 1520-R, Mel 30-R
and Mel 35-R.
Direct effects of BRAFi on NK cells
We next exposed IL-2-activated NK cells to BRAFi for 3 days in
culture to assess the direct effects of BRAFi on NK cells. NK cells
were obtained from three healthy donors. Following a 3-day incu-
bation with different doses of BRAFi, NK cells were co-incubated
with MEL-HO or MEL-HO-R cells for 4 h after which the percent-
ages of degranulating cells (CD107a+) and the level of produced
IFN-γ+ were quantified. The results show that neither vemurafenib
nor dabrafenib reduced the frequency of responding NK cells, sug-
gesting that the BRAFi tested here do not suppress NK-cell effector
functions. Moreover, we noticed that the MEL-HO-R cells induced
a more potent NK-cell response than the parental MEL-HO cells
(Fig. 2).
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Figure 2. Effects of BRAFi on NK-cell degranulation and cytokine
response. Degranulation (CD107a) and cytokine (IFN-γ) responses of
BRAF-treated, IL-2-activated NK cells were assessed by flow cytometry
following 4 h in the absence (U) or presence of MEL-HO-P (P) or MEL-HO-
R (R) target cells at 1:1 E:T ratio. Data are expressed as the geometric
MFI ± SEM of the results pooled from three different donors. Aggregate
values of IFN-γ+CD107a−, IFN-γ−CD107a+ and IFN-γ+CD107a+ were
compared by Bonferroni’s multiple comparison test following 2-way
ANOVA test and the level of significance indicated as *p < 0.05, **p <
0.005, ***p < 0.005.
NK cells lyse both BRAFi-sensitive and BRAFi-resistant
melanoma cell lines
Allogeneic IL-2 activated human NK cells from healthy donors
were used as effectors against either the BRAFi-resistant, and the
respective parental, BRAFi-sensitive melanoma cell line. IL-2 acti-
vated donor NK cells lysed all four sets of BRAFi-sensitive and
BRAFi-resistant cells (Fig. 3). 1520-R cells were more resistant
to NK-cell-mediated lysis than parental 1520 cells (p = 0.0397,
0.0044 and 0.0018 for E:T ratios 12:1, 6:1 and 3:1, respectively).
In contrast, MEL-HO-R cells were more susceptible to NK-cell-
mediated lysis than parentalMEL-HO cells (p= 0.0012 and 0.0234
for E:T ratios 6:1 and 3:1, respectively). No significant differences
were detected in the killing rates of sensitive and resistant SK-
MEL-37 and COLO-38 cells.
Immunomodulatory effects of BRAFi and HLA class I
molecules on NK-cell cytotoxicity
We next quantified and compared HLA class I APM component
and receptor ligand expression on 1520 and MEL-HO cells as well
as on 1520-R and MEL-HO-R cells by flow cytometry analysis
of cells stained with mAbs. The most interesting result was the
significantly lower HLA class I antigen expression on MEL-HO-
R cells as compared to the parental MEL-HO cells (p = 0.0069,
n = 7, Students’ paired t-test, Fig. 4A). Analysis of of APM com-
ponent expression in these two paired cell lines revealed that
BRAFi-resistant MEL-HO-R cells had downregulated HLA-A and
β2-microglobulin (Supporting Information Fig. 1). Interestingly,
1520-R cells, which were killed less effectively by NK cells than
1520 cells, displayed an upregulation of HLA class I molecule
surface expression, although the difference between parental and
resistant cells did not reach statistical significance (Fig. 4A). The
expression of HLA class I molecules was comparable between the
parental and resistant variants of COLO-38, whereas the resis-
tant variant of SK-MEL-37 cells slightly downregulated HLA class
I molecules (data not shown).
To dissect the potential role of HLA class I molecules in con-
trolling NK cells susceptibility of 1520R, HLA class I molecule
masking was performed (Fig. 4B). The HLA class I-specific block-
ing mAb restored susceptibility of these cells to NK-cell-mediated
lysis, increasing their lysis up to the levels of the related parental
BRAFi sensitive cells. On the other hand blocking activating recep-
tors on NK cells had no detectable effect on the extent of killing
between parental and resistant 1520 cell line. Our data clearly
shows that NK-cell inhibition by HLA class I molecules plays a role
in the lower extent of lysis by NK cells of 1520R cells than of the
parental 1520 cells.
MEL-HO-R cells displayed reduced expression of MICA/B
(p = 0.0033, n = 4), ligands of the activating receptor NKG2D,
and increased expression of the PD-1 ligand PD-L1 (p < 0.0001,
n = 6). 1520-R cells, compared to 1520 cells, displayed enhanced
expression of PD-L1 (p = 0.0092, n = 4) and of CD155 (p =
0.0192, n = 4), ligand of the inhibitory receptor TIGIT and of the
activating receptor DNAM-1 (Fig. 4A).
To define the potential role of PD1/PD-L1 inhibitory interac-
tion in the NK-cell-mediated lysis of melanoma BRAFi-resistant
variants anti PD1 antibodies were used to block the interaction
of PD-1 with its ligand PD-L1. No major changes in the killing
capacity of PD1 expressing NK cells against 1520-R and MEL-HO-
R were observed (Supporting Information Fig. 2). Therefore, it is
conceivable that MEL-HO-R cells increased NK-cell susceptibility is
caused at least in part by their downregulated HLA class I antigen
expression levels.
Figure 3. Susceptibility of both BRAFi-sensitive and BRAFi-resistantmelanoma cells to NK-cell-mediated lysis. IL-2-activated NK cells were used as
effectors and BRAFi-sensitive (parental) and resistant (drug resistant) counterparts of the 1520, COLO-38, MEL-HO and SK-MEL-37 melanoma lines
as targets in a standard chromium release assay. Data are expressed as percent lysis and are pooled from triplicates of at least three independent
experiments. *p < 0.05, **p < 0.005 by Bonferroni’s multiple comparison test following two-way ANOVA test.
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Figure 4. Differential expression of NK-cell recep-
tor ligands by BRAFi-sensitive and BRAFi-resistant
melanoma cells and masking HLA class I molecules
on BRAFi-sensitive and -resistant cell lines
enhances NK-cell cytotoxicity. BRAF-I resistance
(resistant) was introduced to parental MEL-HO and
1520 melanoma cell lines (parental). (A) Changes in
cell surface expression of NK-cell receptor ligands
HLA-A,B,C, CD112, CD155, PD-L1 and MIC-A/B upon
acquisition of BRAFi resistance were determined
by flow cytometry. Representative histograms are
included for parental (gray) and resistant (black)
MEL-HO cells and parental (gray) and resistant
(black) 1520 cells. Data are expressed as mean ± SD
of the indicated numbers of samples/experiments.
MelHO: HLA A,B,C p= 0.0069, PD-L1 p< 0.0001, n= 6,
MICA/B p = 0.0033, n = 4 by paired Student’s t-test.
1520: PD-L1 p= 0.0092, n= 4 and of CD155 p= 0.0192,
n = 4 by paired Student’s t-test. (B) α-HLA class I
IgM antibody (clone A6/136) was used to mask HLA-
I molecules on BRAFi-sensitive and BRAFi-resistant
1520 cells. Melanoma cells were then exposed to
IL-2-activated NK cells. To block NK-cell receptors,
IL-2-activated NK cells were pre-incubated with the
indicated blocking antibodies (α-DNAM 1 mAb F5
IgM and α-NKG2D mAb BAT221 IgG1) prior to coin-
cubation with targets. The data are displayed as
the mean ± SD of individual samples pooled from
three independent experiments. *p< 0.05 by Bonfer-
roni’s multiple comparison test following two-way
ANOVA test.
NK-cell cytotoxicity of short-term BRAFi-treated and
established BRAFi-resistant melanoma cells
Using freshly established primary melanoma cells, we evaluated
the effect of BRAFi on their NK-cell susceptibility after short-term
drug exposure. Mel 30 and Mel 35 cells were treated with vemu-
rafenib for 24 h prior to be exposed to NK cells. Vemurafenib
treated cells appear to be significantly less susceptible to NK-cell
killing than the parental cells (Mel 30 12:1 p = 0.0128 and 6:1
p = 0.0476, Mel 35 12:1 p = 0.0322 and 6:1 p = 0.0457, 5A).
This difference may be caused at least in part by the significant
upregulation of HLA class I antigen expression on the vemurafenib
treated Mel 30 and Mel 35 cells (Mel 30 p = 0.0153, Mel 35 p =
0.0371, Fig. 5B). Similar results were obtained using dabrafenib
(Supporting Information Fig. 3).
Additional evidence in support of the role of the increased HLA
class I expression in the resistance of the short-term BRAFi-treated
primary melanoma cells to NK cells mediated killing, comes from
the lack of any significant changes in the surface expression of
other NK-cell ligands on both Mel 30 and Mel 35 (Supporting
Information Fig. 4).
Vemurafenib-resistant variants were subsequently generated
from Mel 30 and Mel 35 parental cells and NK cells susceptibility
was measured. With the long-term treatment of vemurafenib,
Mel 30-R cells became significantly more susceptible to NK-cell
killing than their parental cell (6:1 p = 0.0303, 3:1 p = 0.0256,
Fig. 6A). In contrast, Mel 35-R cells showed at most a slightly
reduced susceptibility to NK-cell recognition, as compared to
their parental cells. A reduction of surface expression of HLA class
I was again observed in BRAFi-resistant Mel 30-R cells. While
C© 2015 The Authors. European Journal of Immunology published by
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Figure 5. NK-cell susceptibility of primary melanoma cells and surface expression of HLA class I antigens after short-term treatment with
vemurafenib. (A) Primary melanoma cells obtained from two different patients (Mel 30, top and Mel 35, bottom) were treated (or not) with
vemurafenib for 24 h and then exposed to NK cells at the indicated E:T ratios. NK-cell recognition of these melanoma lines was measured by
specific lysis. A representative of three individual experiments showing the lysis of Mel 30 and Mel 35 (left) and statistical significance between
the killing of Mel 30, Mel 35 parental and Mel 30, Mel 35 vemurafenib at two different indicated E:T ratios (right) are shown. Data are expressed
as the mean ± SD of triplicates pooled from three independent experiments. Mel 30 12:1 p = 0.0128 and 6:1 p = 0.0476, Mel 35 12:1 p = 0.0322 and
6:1 p = 0.0457 paired Student’s t-test. (B) Primary melanoma cells (Mel 30 and Mel 35) were treated with vemurafenib for 24 h and the cells were
then stained with mAb W6/32 directed against HLA A, B, C. Representative histograms for Mel 30 and Mel 35 where parental (gray), treated with
vemurafenib (black) and isotype (dashed) are included. The mean ± SD of individual samples pooled from three independent experiments (right)
is also shown. Mel 30 p = 0.0153, Mel35 p = 0.0371, paired Student’s t-test.
vemurafenib resistant Mel 30-R cells expressed less HLA class
I compared to related parental cell (p = 0.0159, Fig. 6B),
vemurafenib resistant Mel 35-R cells expressed a significantly
higher level of HLA class I antigens than their parental cells
(p = 0.0203 Fig. 6B). Therefore, the results observed with the
primary melanoma samples Mel 30 and Mel 35 recapitulate the
patterns obtained with the cell lines after the generation of the
resistant variants. Mel 30 resembles MEL-HO both in terms of
susceptibility to NK-cell killing and in terms of HLA class I antigen
surface expression, while Mel 35 cells resemble 1520 cells in
terms of the increased HLA class I antigen surface expression on
the BRAFi-resistant cells.
Interestingly, as observed with MEL-HO-R and 1520-R cells,
Mel 30-R and Mel 35-R cells express detectable levels of the PD-1
ligand (PD-L1) in a higher proportion of cells, as compared to that
measured in the related BRAFi-sensitive cells (p value = 0.0042
and 0.0006, respectively, Supporting Information Fig. 5). It should
be noted that there is no correlation between the expression levels
of PD-L1 on Mel 30, and Mel 35 cells and their corresponding
variants and their susceptibility to NK-cell-mediated lysis.
C© 2015 The Authors. European Journal of Immunology published by
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Figure 6. Susceptibility to NK-cell cytotoxicity and HLA class I surface expression of BRAFi-resistant primary melanoma cells. (A) Primary
melanoma cells collected from two patients (Mel 30, top and Mel 35, bottom) were cultured for 4 weeks with vemurafenib and then exposed
to NK cells at the indicated E:T ratios. NK-cell recognition was measured by specific lysis. A representative of three independent experiments
showing specific lysis of Mel 30 and Mel 35 (left), and statistical significance between the killing of Mel 30, Mel 35 parental and Mel 30, Mel 35
resistant cells (right) are shown. Data are expressed as the mean ± SD of triplicates samples pooled from three independent experiments. Mel 30
6:1 p = 0.0303, 3:1 p = 0.0256, paired Student’s t-test. (B) Primarymelanoma cells (Mel 30 andMel 35) were treated with vemurafenib for 4 weeks and
the cells were then stained with HLA class I antibody W6/32. Representative histograms for Mel 30 and Mel 35 where parental (gray) and resistant
(black) and isotype (dashed) are included (left). Data are also expressed as the mean ± SD of individual samples pooled from three independent
experiments., Mel 30 p = 0.0159, Mel 35 p = 0.0203, paired Student’s t-test.
Discussion
We provide evidence that NK cells are able to lyse melanoma cell
lines that have acquired resistance to BRAFi and BRAFi do not sup-
press NK-cell effector functions. These results provide arguments
to consider harnessing NK-cell-mediated cytotoxicity to improve
the success of therapies in melanoma patients harboring mutant
BRAF, and in particular those who have become refractory to
BRAFi treatment. Acquisition of BRAFi resistance is associated
with decreased HLA class I antigen expression in the case of the
MEL-HO cell line and in less extent inMel 30 primary cells while an
increase of the same is clearly observed in 1520 cell line andMel 35
primary cells. A large screening of the melanoma cell lines surfaces
searching for molecules known to modulate NK cells susceptibility
leads to the appreciation of the HLA class I antigens as potential
regulatory molecule for the NK-BRAFi-resistant melanoma cross
talk. The upregulation of HLA class I antigens contribute to the
drug-resistant cells reduced susceptibility to NK-cell cytotoxicity.
Masking of HLA class I molecules results in restored susceptibility
of 1520R cells to the levels of parental 1520 cells. It is tempting
to speculate that HLA class I APM molecule downregulation in
MEL-HO-R cells might have led to engagement of fewer inhibitory
KIRs in NK cells. This in turn might render drug-resistant MEL-HO-
R cells more susceptible to NK-cell-mediated lysis. On the other
C© 2015 The Authors. European Journal of Immunology published by
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hand, acquisition of resistance to BRAFi in 1520 cells correlated
with a tendency to upregulate HLA class I APM molecules and
a reduced ability of NK cells to kill the BRAFi-resistant variant.
The HLA class I masking experiment performed on 1520 cell pairs
results in an increased NK susceptibility of BRAFi-resistant and
related susceptible melanoma cells suggesting that biological ther-
apy interfering with the HLA-KIR checkpoint may be an effective
strategy to target drug-resistant melanoma cells for destruction by
NK cells. However, it should be noted that in our experiments the
use of a pan anti-HLA class I monoclonal antibody could under-
estimate the surface expression levels changes of either specific
classical HLA class I alleles (HLA-C, HLA-B) or nonclassical HLA
class I molecules (HLA-E, HLA-G). Therefore, this part of the study
deserves a more detailed analysis at higher resolution.
The expression of PD-L1 was enhanced on MEL-HO-R and
1520-R, as well as in Mel 30-R and Mel 35-R confirming
previous work showing that activation of MAPK, which is a major
mechanism of acquired BRAFi resistance, promotes PD-L1 expres-
sion [8]. PD-L1 exerts its immunosuppressive role mainly through
engaging PD-1 on activated T cells, however there are precedents
for potential roles of PD-1 in NK-cell function. Indeed, the expres-
sion of PD-1 on NK cells may predict responses to anti-PD1/PD-L1
therapies in patients with multiple myeloma [19]. PD-1 expres-
sion on blood leukocytes, including NK cells, could be a useful
indicator of disease progression in patients with renal cell car-
cinoma [23]. However, our results of the blocking experiments
with PD-L1-specific mAbs argue against an involvement of this
molecule PD-L1 in NK-cell recognition of the BRAFi-resistant vari-
ants. BRAFi have been shown to exert immunomodulatory effects,
such as upregulation ofmelanoma antigens in vitro [24], increased
T-cell infiltration in tumors [25], reversed immunosuppression
by myeloid-derived suppressor cells [26] and enhanced PD-L1
expression [8]. Vemurafenib causes changes in the proportions of
peripheral blood lymphocytes, with decreased CD4+ T cells and
increased NK cells [27]. In a mouse model, a vemurafenib analog
downmodulated expression of CCL2 on melanoma cells, result-
ing in increased intratumor CD8+ T cell/Treg ratio and enhanced
proportion of NK cells [28, 29]. Our results suggest that suscep-
tibility to NK-cell-mediated lysis is preserved despite the acquisi-
tion of BRAFi resistance. Based on these results, we propose that
IL-2 activated allogeneic NK cells could be added to the arsenal of
immunotherapies to be combined with targeted therapies.
The evidence that NK cells participate in tumor immunity
is clear. Selective NK-cell immunodeficiencies, albeit rare, are
characterised by high prevalence of malignancy. Among 21 cases
described, six developed malignancies, including one case of pedi-
atric melanoma, one sarcoma and four hematological malignan-
cies [30]. An 11-year longitudinal study in a large cohort showed
increased cancer prevalence in individuals with a low NK-cell
cytotoxicity in peripheral blood [31]. NK-cell-deficient mice fail
to reject transplanted tumors [32]. NK cells are being tested in
several clinical trials that aim to either harness host NK cells
or use donor NK cells in adoptive cell therapy [33]. NK cells,
together with CTL, mediate the effect of high dose IL-2 treatment
reported in early clinical trials in patients with metastatic can-
cers [34]. Moreover, increased frequency of CD56dim, KIR+CD57+
highly cytotoxic NK cells in melanoma infiltrated lymph nodes
correlate with patient clinical outcome [35]. The results of our
study provide further arguments in favor of considering adoptive
NK-cell therapy in melanoma patients that develop resistance to
BRAFi.
Materials and methods
Cell lines and primary cells
All melanoma cell lines were maintained in RPMI 1640 medium
supplemented with 10% heat inactivated fetal calf serum (FCS),
1% penicillin/streptomycin and 50 μM 2-marcapto ethanol. Cells
were passaged every 2–3 days. Primary melanoma cell lines car-
rying the BRAFV600E mutation were obtained from patients after
informed consent, according to previously described procedure
[36] at the Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy. Melanoma patients were named Mel 30 and Mel 35.
Primary blood NK cells were isolated by negative selection with
immunomagnetic beads (Miltenyi) according to manufacturer’s
protocol. Isolated NK cells were maintained in minimal essen-
tial medium with alpha-modification supplemented by 10% heat
inactivated FCS, 2nM L-Glutamine and 1000 IU/mL IL-2 Proleukin
(Novartis, Basel) for 48 h.
Antibodies and protein reagents
The following antibodies for flow cytometry were purchased
from BioLegend unless otherwise stated: anti-CD3 (clone
UCHT1) APC-Cy7, anti-CD56 [clone HCD56] Brilliant Violet 605,
anti-CD112 (clone TX31) R-phycoerythrin (PE), anti-CD155
(clone TX24) PE, anti-CD274 (PD-L1, clone 29E.2A3) PE or
anti-CD274 (PD-L1, clone 10F.9G2) PE, anti-HLA-A, B, C (clone
W6/32) PE, anti-MIC-A/B (clone 6D4) Alexa Fluor 647, anti-
CD107a (clone H4A3) Alexa Fluor 647, anti-IFN-γ (clone 4S.B3)
PE (from eBioscience). Antibody specific for HLA class I APM
components include: HLA-A-specific mAb LGIII-147.4.1, HLA-B,
C-specificmAb B1.23.2, HLA-A, B, C-specificmAb TP25.99.8.4, β2-
microglobulin-specific mAb NAMB-1, calnexin-specific mAb TO-
5, calreticulin-specific mAb TO-11 and tapasin-specific mAb TO-
3, HLA-DR, DQ, DP-specific mAb LGII-612.14. Cells were intra-
cellularly stained with Delta-specific mAb SY-5, LMP2-specific
mAb SY-1, LMP7-specific mAb HB2, LMP10-specific mAb TO-7,
TAP1-specific mAb NOB1, TAP2-specific mAb NOB2, calnexin-
specific mAb TO-5, calreticulin-specific mAb TO-11 and tapasin-
specific mAb TO-3 [37–44]. The isotype matched IgG1 mAb MK2-
23 was used as a specificity control. Cell staining was detected
by PE-labeled anti-mouse IgG antibody. mAb BAM 195 (anti-
MICA, IgG1) and mAb 6D4 (anti-MICB, IgG1) were provided by
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Veronika Groh (Fred Hutchinson Cancer Research Center, Seattle,
WA, USA); M295 (anti-ULBP1, IgG1), M310 (anti-ULBP2, IgG1),
M550 (anti-ULBP3, IgG3) and M478 (anti-ULBP4, IgG1) were
gifted by D. Cosman (Amgen, Seattle, WA, USA; mAb L95 (anti-
CD155, IgG1) and mAb L14 (anti–CD112, IgG2a) were devel-
oped and characterized as described in Bottino et al. [45]. Cell
staining was detected by PE-labeled anti-mouse IgG antibody.
For the masking of HLA class I and blocking NK cell recep-
tors the following antibodies were used: anti-HLA-A,B,C (clone
A6/136, IgM), anti-DNAM-1 (clone F5, IgM), anti-NKG2D (clone
BAT221, IgG), anti-CD-57 (clone HNK-1, IgM), all kindly provided
from Alessandro Moretta (Laboratory of Molecular Immunol-
ogy, Department of Experimental Medicine, University of Gen-
ova, Italy) and anti-PD1 (clone EH12.2H7, LEAFTM purified IgG1,
Biolegend).
Generation of BRAFi-resistant cells
Melanoma cell lines with acquired BRAFi resistance (COLO-38-R,
SK-MEL-37-R, 1520-R, MEL-HO-R) were generated by propagat-
ing parental COLO-38, SK-MEL-37, 1520 and MEL-HO cells in
increasing concentrations of BRAFi (up to 5 μM). MEL-HO cells
in the presence of 5 μM vemurafenib failed to produce BRAFi-
resistant cells, whereas 30 days of culture in the presence of
5 μM dabrafenib gave rise to MEL-HO cells with increased resis-
tance toward dabrafenib and cross-resistance to vemurafenib. At
the end of cell culture period that induced resistance, resistant
cells were isolated from each of the cell lines and cultured in
RPMI 1640 medium supplemented with 2 mmol/L L-glutamine,
10% FCS and 500 nM BRAFi. Prior to cytotoxicity assays and to
flow cytometry, both sensitive and resistant cells were cultured
in BRAFi-free medium for up to 2 weeks. To check the short-
term effect of the drugs on primary cells, Mel 30 and Mel 35
were treated for 24 h before the experiment by 5 μM of either
vemurafenib or dabrafenib. For the generation of Mel 30-R and
Mel 35-R the relative parental cells were propagated for 30 days
in the presence of 5 μM vemurafenib and after the appearance
of the resistant cells the concentration of BRAFi was kept at
500 nM. Cytotoxicity and flow cytometry experiments were per-
formed without removing the drug from the culture medium. We
gene sequenced the resistant cell variants 1520-R and MEL-HO-R
to confirm that they had conserved themutant BRAFV600E genotype
and were not an outgrowth of potentially pre-existing BRAFWT
cells (Supporting Information Fig. 6A). The BRAFWT MV3 cell
line was used as control. Western blots showed that SK-MEL-37-
R and COLO-38-R cells, but not 1520-R cells or MEL-HO-R cells,
had a truncated version of BRAF, which no longer binds BRAFi
(Supporting Information Fig. 6B and not shown), and is known to
confer resistance in about 30% of patients progressing on BRAFi
therapy [46]. Therefore it is likely that SK-MEL-37-R and COLO-
38-R cells acquire resistance due to the truncated BRAF. Themech-
anism of resistance to BRAFi in 1520-R and in MEL-HO-R cells are
unknown.
Cell ATP luminescence assay
Melanoma cells were cultured in tissue culture treated 96-well
plates in the presence of various concentrations of dabrafenib,
vemurafenib or DMSO for 4 days at 37°C and 5% CO2. Relative
cell ATP levels were assayed by CellTiter-Glo homogenous lumi-
nescence assay (Promega) according to manufacturer’s protocol
and luminescence was detected on a BMG OPTMA microplate
reader.
Cytotoxicity assay
Melanoma target cells were labeled with Na[51Cr]O4 at 37°C for
1 h and co-incubated with NK effector cells in complete medium
at 37°C for 4 h. The 51Cr activity of the supernatant was mea-
sured with a gamma-counter. Percent specific lysis was calculated
as ([cpm experimental release − cpm spontaneous release]/[cpm
maximum release − cpm spontaneous release]) × 100. Sponta-
neous release represents the 51Cr release from target cells alone.
Experimental release represents the release from target cells incu-
bated with effector cells and maximum release represents the 51Cr
content of resuspended target cells.
Flow cytometry
Melanoma cells were detached nonenzymatically by 1× PBS with
2 mM EDTA. Dead cells were excluded by Hoechst viability
stain 0.5 μg/mL. For cell surface staining, cells were blocked
in Human TruStain FcX reagent (BioLegend) prior to staining
with fluorochrome conjugated mAb and 7-AAD viability stain fol-
lowed by one wash in FACS-buffer. For the degranulation and
cytokine response assay, melanoma cells were labeled with DiO
tracer dye (Life Technologies) according to manufacturer’s pro-
tocol and cocultured with NK cells for 4 h at 37°C, 5% CO2 in
the presence of 1:100 anti-CD107a antibody, 5 μM monensin
and 3 μg/mL brefeldin A. Following coculture, cells were stained
with antibodies to cell surface markers and fixable viability dye
(eBioscience). Intracellular IFN-γ was detected by anti-IFN-γ anti-
body (eBioscience) according to manufacturer’s protocol. All cells
were acquired with a BD LSR-Fortessa flow cytometer (BD Bio-
sciences). Flow cytometry data were analyzed by FlowJo Soft-
ware (TreeStar). Representative flow cytometry gating diagrams
are shown in Supporting Information Fig. 7.
Western blot assay
Adherent melanoma cells were lysed in RIPA buffer (Thermo Sci-
entific) supplemented with Complete Proteinase Inhibitor tablets
(Roche) and quantified by bicinchoninic acid whole protein assay
prior to SDS-PAGE separation under reducing conditions. Sep-
arated proteins were transferred to a PVDF membrane via the
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WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2016. 46: 409–419 Immunomodulation 417
iBlot dry blotting system (Life Technologies) and blocked in 10%
cleared skimmed milk followed by detection with rabbit-anti-
BRAF mAb clone 55C6 (Cell Signaling Technology). Equal protein
loading was confirmed by membrane stripping and reprobing with
anti-Actin antibody (Cell Signaling Technology).
Statistical analysis
Two-tailed Student’s t-test, one sample t-test and two-way para-
metric analysis of variance (ANOVA) with Bonferroni multiple-
comparison test were used to determine statistical significance; in
these tests a p value of less than 0.05 was considered significant.
Tests were performed with GraphPad Prism version 5.03 and 6.00
(GraphPad Software).
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